Cargando…

Targeted therapy in CLL: changing the treatment paradigm

Detalles Bibliográficos
Autores principales:	Schneider, Christof, Steinbrecher, Daniela, Stilgenbauer, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592289/ https://www.ncbi.nlm.nih.gov/pubmed/31258844 http://dx.doi.org/10.18632/oncotarget.26964

Ejemplares similares

Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021)

From Biology to Therapy: The CLL Success Story
por: Yosifov, Deyan Y., et al.
Publicado: (2019)

Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm
por: Scheffold, Annika, et al.
Publicado: (2020)

To β or Not to β: How Important Is β-Catenin Dependent and Independent WNT Signaling in CLL?
por: Urbanek, Karol D., et al.
Publicado: (2022)

CLL kinetics in the tumor microenvironment
por: Sun, Clare, et al.
Publicado: (2017)

Tumor suppressors revival in CLL
por: Carrà, Giovanna, et al.
Publicado: (2017)

The paradigm change in keratoconus therapy
por: Seiler, Theo
Publicado: (2013)

Changing paradigms in treatment of larynx cancer
por: Chone, Carlos Takahiro
Publicado: (2014)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
por: Simon, Florian, et al.
Publicado: (2023)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
por: Langerbeins, Petra, et al.
Publicado: (2023)

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
por: Pflug, Natali, et al.
Publicado: (2021)

Microvesicles in CLL: predictor of disease progression/relapse
por: Maiti, Guru P., et al.
Publicado: (2017)

Targeting CLL-1 for acute myeloid leukemia therapy
por: Ma, Hongbing, et al.
Publicado: (2019)

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
por: Al-Sawaf, Othman, et al.
Publicado: (2021)

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group
por: Jaramillo, Sonia, et al.
Publicado: (2019)

The pulmonary nodule: change of paradigm
por: Diederich, Stefan
Publicado: (2015)

The Changing Paradigm of Obesity Care
por: Madhu, S. V.
Publicado: (2022)

Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL
por: Cuesta-Mateos, Carlos, et al.
Publicado: (2021)

Rapid transitions in the standard of care for chronic lymphocytic leukemia (CLL)
por: Seymour, Erlene K.
Publicado: (2019)

Changing the diabetes treatment paradigm from glucose control to cardiorenal protection
por: Ekanayake, Preethika, et al.
Publicado: (2021)

Bladder cancer — When will the paradigm change?
por: Kekre, Nitin S.
Publicado: (2011)

Changing Paradigms in the Practice of Cardiac Anesthesiology
por: Kapoor, Mukul C.
Publicado: (2022)

Validating genomic tools for precision medicine in CLL: ERIC leads the way
por: Wiestner, Adrian
Publicado: (2021)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy
por: Yoon, Sang Min
Publicado: (2023)

Mutations driving CLL and their evolution in progression and relapse
por: Landau, Dan A., et al.
Publicado: (2015)

Endocrine hypertension: Changing paradigm in the new millennium
por: Baruah, Manash P., et al.
Publicado: (2011)

Protozoans of tissue and blood: A changing paradigm
por: Parija, Subhash Chandra
Publicado: (2016)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Critical molecular pathways in CLL therapy
por: Ferrer, Gerardo, et al.
Publicado: (2018)

Changing paradigm of men's health
por: Khera, Mohit
Publicado: (2016)

Augmenting NF-κB in poor-risk CLL: A general paradigm for other cancers?
por: Tuveson, David, et al.
Publicado: (2015)

Poster: CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients
por: Öztürk, Selcen, et al.
Publicado: (2021)

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?
por: Kaplinsky, Edgardo
Publicado: (2015)

IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling
por: Maity, Palash C., et al.
Publicado: (2020)

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
por: Stilgenbauer, Stephan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ohkd1tod42op611himevradi5u